Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66.5M
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
9.17M
-
Shares change
-
+33.5K
-
Total reported value, excl. options
-
$11.7M
-
Value change
-
+$40.1K
-
Put/Call ratio
-
0.04
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$1.28
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) as of Q4 2023
28 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.17M shares
of 66.5M outstanding shares and own 13.79% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (3.88M shares), FMR LLC (2.92M shares), DAFNA Capital Management LLC (1.11M shares), VANGUARD GROUP INC (286K shares), VICTORY CAPITAL MANAGEMENT INC (272K shares), Sarissa Capital Management LP (185K shares), Exome Asset Management LLC (178K shares), GEODE CAPITAL MANAGEMENT, LLC (123K shares), RENAISSANCE TECHNOLOGIES LLC (54.6K shares), and STATE STREET CORP (41.7K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.